<p>Vyjuvek is a medicine used to treat wounds in patients with dystrophic epidermolysis bullosa. Dystrophic epidermolysis bullosa is an inherited disease of the skin that makes the skin very fragile and causes severe blistering and scarring. Vyjuvek is intended for patients with dystrophic epidermolysis bullosa who have mutations affecting the <em>COL7A1 (</em>collagen type VII alpha 1 chain) gene.</p><p>Dystrophic epidermolysis bullosa is rare, and Vyjuvek was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 16 April 2018. Further information on the orphan designation can be found on the EMA <a href="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2012">website</a>.</p><p>Vyjuvek contains the active substance beremagene geperpavec. </p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the<em> collagen type VII alpha 1 chain (COL7A1) </em>gene, from birth</p></div>
Therapeutic Area (MeSH)
ATC Code
D03AX16
ATC Item
N/A
Pharmacotherapeutic Group
Preparations for treatment of wounds and ulcers
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Beremagene geperpavec | N/A | Beremagene geperpavec |
EMA Name
Vyjuvek
Medicine Name
Vyjuvek
Aliases
N/ANo risk management plan link.
